

TABLE 3. The lack of influence of age of donors on tolerance induction in B10 mice

Recipient ^a	Group	Spleen cells (5×10 ⁶ /g)	CP (200 mg/kg)	B10.BR skin graft survival (days)	No. mice	MST±SD
B10(8w)	1	B10.BR(6w)	-	9, 9, 9, 10, 13	5	10.0±1.7
	2	B10.BR(6w)	+	23, 24, 39, 39, 46, 60, 74, 81, 81, 81, 88	11	57.8±24.5
	3	B10.BR(12w)	-	9, 10, 10, 11, 11	5	10.0±1.0
	4	B10.BR(12w)	+	20, 21, 25, 30, 39, 53, 53, 60, 60, 95	10	45.6±23.4 ^b
	5	B10.BR(37w)	-	8, 9, 9, 10, 11	5	9.4±1.1
	6	B10.BR(37w)	+	19, 20, 20, 23, 30, 53, 53, 81, 81, 109	10	48.9±32.1 ^b

^a See footnote^a of Table 1.

^b Not significant compared with group 2 by the *U* test.

by complexities related to the tolerogenic spleen cell populations, as already indicated in another study of this series.³ Namely, in the induction of tolerance with the combined treatment of allogeneic spleen cells plus CP, the antigenicity of the spleen cells, the numbers of T cells, and the numbers of Ia positive cells also may be as crucial as the numbers of the stem cells contained in the preparation.

In summary, the age of adult recipient mice was found crucial to the induction of skin allograft tolerance with allogeneic spleen cells plus CP. By contrast, the age of the donor mice used for tolerance induction did not appear to be crucial for the induction of a tolerant state.

HISANORI MAYUMI⁴
ROBERT A. GOOD
Department of Pediatrics
All Children's Hospital
University of South Florida
College of Medicine/St. Petersburg
St. Petersburg, Florida 33701

⁴Address correspondence to: Hisanori Mayumi, M.D., Division of Cardiovascular Surgery, Research Institute of Angiocardiology, Faculty of Medicine, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812, Japan.

REFERENCES

1. Billingham RE, Brent L, Medawar PB. Quantitative studies on tissue transplantation immunity: III. Actively acquired tolerance. *Philos Trans R Soc Lond [Biol]* 1956; 239: 357.
2. Billingham RE, Brent L. A simple method for inducing tolerance of skin homografts in mice. *Transplant Bull* 1957; 4: 67.
3. Mariani T, Martinez C, Smith JM, Good RA. Age factor and induction of immunological tolerance to male skin isografts in female mice subsequent to the neonatal period. *Ann NY Acad Sci* 1960; 87: 93.
4. Good RA, Martinez C, Gabrielsen AE. Progress toward transplantation of tissue in man. In: Levine SZ, ed. *Advances in pediatrics*; vol 13. Chicago: Year Book Medical, 1964: 93.
5. DiMarzo SJ, Cohen N. Immunogenetic aspects of in vivo allotolerance induction during the ontogeny of *Xenopus laevis*. *Immunogenetics* 1982; 16:103.
6. Schwartz R, Dameshek W. Drug-induced immunological tolerance. *Nature* 1959; 183: 1682.
7. Mayumi H, Himeno K, Shin T, Nomoto K. Drug-induced tolerance to allografts in mice: VI. Tolerance induction in H-2-haplotype-identical strain combinations in mice. *Transplantation* 1985; 40: 188.
8. Shin T, Mayumi H, Himeno K, Sanui H, Nomoto K. Drug-induced tolerance to allografts in mice: I. Difference between tumor and skin grafts. *Transplantation* 1984; 37: 580.
9. Shin T, Himeno K, Mayumi H, Nomoto K. Drug-induced tolerance to allografts in mice: III. Prolongation of skin graft survival by tolerance induction in congenic mice disparate in the major H-2 antigens. *Transplantation* 1985; 39: 333.
10. Good RA, Dalmaso AP, Martinez C, Archer OK, Pierce JC, Papermaster BW. The role of the thymus in development of immunologic capacity in rabbits and mice. *J Exp Med* 1962; 116: 773.
11. Miller JFAP. Role of the thymus in transplantation immunity. *Ann NY Acad Sci* 1962; 99: 340.
12. Nomoto K, Mayumi H, Himeno K, Watanabe Y, Mitani M, Tokuda N. Allograft rejection and immune responses against allogeneic antigens in neonatally thymectomized mice. *Transplantation* 1985; 41: 209.
13. Sidorovich SY, Latsinik NV. Age-related change in the content of clonogenic stromal precursor cells in the hematopoietic organs of guinea pigs. *Bull Exp Biol Med* 1978; 86: 945.
14. Hunt SV. Surface antigens characterizing lymphopoietic stem cells in rats. In: Thierfelder S, Rodt H, Kolb HJ, eds. *Immunobiology of bone marrow transplantation*. New York: Springer-Verlag, 1980: 193.
15. Maier T, Holda JH, Claman HN. Natural suppressor (NS) cells: member of the LGL regulatory family. *Immunol Today* 1986; 7: 312.

Received 29 February 1988.

Accepted 14 March 1988.

FK506: A NOVEL IMMUNOSUPPRESSIVE AGENT CHARACTERISTICS OF BINDING AND UPTAKE BY HUMAN LYMPHOCYTES

Several studies indicate FK506, a novel compound (Fig. 1), to be a potent immunosuppressive agent (1). Like cyclosporine, FK506 is isolated from a fungus, *Streptomyces tsukubaensis*, and is hydrophobic. Although cyclosporine is a peptide of larger molecular weight than FK506, both are cyclic compounds, with

cyclosporine being more rigid than FK506. Recent in vitro studies suggest that FK506 possesses immunosuppressive properties similar to those of cyclosporine, implying that the mechanism of action for these two drugs may be similar as well. The immunosuppressive effect of FK506 is several-hundred-fold




FIGURE 1. FK506.

greater than that of cyclosporine (2, 3). As previously demonstrated for cyclosporine, the inhibitory effect of FK506 is seen in mixed leukocyte culture and on secondary proliferation of alloreactive T cells harvested from MLC or propagated from organ transplant biopsies (4). The published data further show that immunosuppression by FK506 may be mediated through an inhibition of interleukin-2 release (2, 4), again emphasizing the similarities between cyclosporine and FK506.

In this report we describe the characteristics and kinetics of cellular uptake and intracellular binding of FK506 by human peripheral blood lymphocytes. PBL were isolated from the blood of four healthy donors and depleted of their monocyte content as described previously (5).

Binding and uptake of FK506 by PBL is shown in Figure 2. The uptake of FK506 by PBL is a saturable process, with saturation occurring at an approximately $0.5 \mu\text{M}$ concentration of the drug. Scatchard analysis of the binding data is consistent with two distinct classes of binding sites—one with a $K_d = 3.9 \pm 1.8 \times 10^{-8} \text{ M}$ for the high affinity sites, and the second with a $K_d = 5.2 \pm 0.8 \times 10^{-6} \text{ M}$ for the low affinity sites. This analysis further reveals that there are $5.6 \pm 1.0 \times 10^4$ and $2.5 \pm 0.9 \times 10^6$ high- and low-affinity binding sites, respectively, per cell. LeGrue et al. (7) have reported that binding of cyclosporine by normal PBL also exhibits two classes of binding sites with a K_d of $2-6 \times 10^{-9} \text{ M}$ for the high-affinity site and a K_d of about 10^{-7} M representing a low-affinity site. They have further indicated that only B cells possess high-affinity sites. Our data, together with this information, seem to further delineate the similarities between FK506 and cyclosporine.

Merker and Handschumacher (8) have studied the intracellular localization of cyclosporine by a murine thymoma cell line (BW5147), and have shown that cyclosporine binds to a cytosolic protein (termed *cyclophilin*) with an apparent molecular weight of 15,000–20,000 daltons. More recently, Fabre et al. (9) have shown the presence of a similar protein in a human Burkitt lymphoma cell line (RAJI cells). The dissociation constant for the binding of cyclosporine to cyclophilin has been reported to be approximately $2.2 \mu\text{M}$. We have investigated the binding of FK506 to cytosolic proteins obtained from PBL. The elution profile of FK506 and cyclosporine on a Bio-Gel P-60 exclusion column that had been calibrated with ovalbumin, carbonic anhydrase, cytochrome C, and vitamin B12 is shown in Figure 3. A graph of the log molecular weight versus the ratio of the elution volume to the void volume for the




FIGURE 2. Binding of FK506 by human peripheral blood lymphocytes. Normal human lymphocytes (5×10^6) were incubated for 60 min at 37°C in $250 \mu\text{l}$ of 1% BSA-RPMI 1640 medium containing the indicated concentrations of FK506. The cells were chilled at 0°C for 10 min and washed twice with cold saline, resuspended in phosphate buffer (0.2 M, pH 7.4), and the suspension was used for FK506 determination using the Fujisawa method (6). Results are in $\mu\text{mol}/10^6$ cells.




FIGURE 3. Elution profile of the intracellular proteins of PBL on Bio-Gel P-60. Normal human lymphocytes (100×10^6) cells were incubated for 60 min at 37°C in 4 ml 1% BSA-RPMI 1640 medium containing $2 \mu\text{g}$ FK506 and $1.5 \mu\text{g}$ (^3H) cyclosporine (specific activity $300 \text{ dpm}/\text{ng}$). The cells were chilled at 0°C for 10 min, washed twice with cold saline, and resuspended in Tris buffer (20 mM, pH 7.2) containing 2-mercaptoethanol (5 mM) and sodium azide (0.02%). Cells were disrupted by sonic oscillation (9), the cellular debris was removed by centrifugation at $40,000 \text{ g}$ for 30 min, and the supernate was passed through a Bio-Gel P-6 column to remove protein-free FK506 and cyclosporine. The drugs were then chromatographed on a Bio-Gel P-60 column (40 cm x 1.5 cm) using the same Tris buffer. Utilizing the calibration curve of the molecular weight markers—(a) ovalbumin, (b) carbonic anhydrase, (c) cytochrome C, and (d) vitamin B12—as described in the insert, it appears that both cyclosporine (Δ) and FK506 (\bullet) are associated with a protein or proteins with a molecular weight around 18,000–19,000 daltons.

molecular weight markers is shown in the insert. These data suggest that both FK506 and cyclosporine elute in association with a protein with an apparent molecular weight of approximately 18,000–19,000 daltons. Whether this is incidental or there is in fact only one protein that binds both drugs is not clear at present. But, if a single protein, such as cyclophilin, is involved in the binding of both these drugs, then the question of whether two separate binding sites are involved in this process remains to be investigated. Recently, we have demonstrated that human PBL exposed to FK506 for periods varying from 1 hr to 40 hr are able to take up about 20% more cyclosporine relative to control cells not exposed to FK506 (10). Similarly, FK506 exposed cells show considerably increased sensitivity to cyclosporine (2–4) in terms of mixed lymphocyte reaction and primed lymphocyte tests. This evidence seems to suggest that binding of one drug, for instance FK506, modifies the cellular response to another drug (cyclosporine), resulting in a greater uptake of cyclosporine by the cell.

In summary, kinetics of binding and uptake of FK506 by PBL, and the apparent common association of FK506 and cyclosporine with an intracellular protein, enhances further the similarities between these two immunosuppressive agents.

Acknowledgments. We gratefully acknowledge advice from Professor Adriana Zeevi throughout this work, and the technical assistance of Mrs. Jean Chao and Ms. Jacquelin Randour.

VIJAY WARTY¹
WARREN DIVEN¹
EVAN CADOFF¹
SATORU TODO²
THOMAS STARZL²
AJIT SANGHVI¹

*Departments of Pathology and Surgery
University of Pittsburgh School of Medicine
Pittsburgh, PA 15261*

¹ Department of Pathology.

² Department of Surgery.

REFERENCES

1. Sawada S, Suzuki G, Kanase Y, Takaku F. Novel immunosuppressive agent, FK506: in vivo effects on the cloned T cell activation. *J Immunol* 1987; 139: 1797.
2. Ochiai T, Nakajima K, Nagata M, et al. Effect of a new immunosuppressive agent, FK506, on heterotopic cardiac allotransplantation in the rat. *Transplant Proc* 1987; 19: 1284.
3. Zeevi A, Duquesnoy R, Eiras G, Todo S, Makowka L, Starzl T. In vitro immunosuppressive effects of FR900506 on liver T cells aleoactivation. *Surg Res Commun* 1987; 1: 315.
4. Zeevi A, Duquesnoy R, Eiras G, et al. Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. *Transplant Proc* 1987; 19: 40.
5. Jerrells TR, Dean JH, Richardson GL, Herberman RB. Depletion of monocytes from human peripheral blood mononuclear leukocytes: comparison of the Sephadex G-10 column method with other commonly used techniques. *Immunol Methods* 1980; 32: 11.
6. Kobayashi M, Tamura K, Kaizu T, Tanaka H. A highly sensitive method to assay FR 900506 in plasma. Presented at a satellite workshop (FK900506: a potential breakthrough in immunosuppression) of the European Transplant Society, Gothenburg, Sweden, June 10, 1987.
7. LeGrue SJ, Friedman AW, Kahan BD. Binding of cyclosporine by human lymphocytes and phospholipid vesicles. *J Immunol* 1983; 131: 712.
8. Merker MM, Handschumacher RE. Uptake and nature of the intracellular binding of cyclosporin A in a murine thymoma cell line, BW5147. *J Immunol* 1984; 132: 3064.
9. Fabre I, Fabre G, Lena N, Cano J-P. Kinetics of uptake and intracellular binding of cyclosporine A in Raji cells, in vitro. *Biochem Pharmacol* 1986; 35: 4261.
10. Sanghvi A, Warty V, Zeevi A, et al. FK-506 enhances cyclosporine uptake by peripheral blood lymphocytes. *Transplant Proc* 1987; 19: 45.

Received 21 January 1988.

Accepted 16 February 1988.

AUTOMATED ISOLATION OF MOUSE PANCREATIC ISLETS¹

The development of an automated method for the isolation of human pancreatic islets (1) demonstrated that it is possible to obtain large numbers of intact islets with minimal traumatic action to the islets through a continuous digestion process in which the islets are progressively liberated and saved from the collagenase action. One of the advantages of this procedure is to avoid any chopping, teasing, aspiration through needles, or tissue maceration used in other procedures (2–8) that could result in a considerable traumatic action to the islets. In addition, with other isolation procedures, the predigestion of digestion process is generally stopped at an estimated optimal digestion time, and the isolation is then continued by other means. When the pancreatic digestion is interrupted, part of the pancreas is generally still undigested, other portions are overdigested, and what is left is the portion of the preparation that at the time is optimally dissociated: islets free from exocrine tissue but not yet damaged by the collagenase activity.

The viability of human islets isolated by the automated method has been tested already in different models (9–11) that demonstrated the functional integrity of the islets obtained by this procedure. After these encouraging results, it was decided to test a similar procedure for mouse islet isolation in order to determine whether the number of donor mice required to make a recipient normoglycemic could be reduced. Our original collagenase technique (12) for mouse islet isolation required 24 mice to obtain approximately 1,200 islets for transplantation. In addition, a small scale model of the automated isolation procedure would be useful for the isolation of islets from other small animals, or for the digestion of fetal or neonatal pancreases of larger mammals, including man.

Six male B10.BR/SgSnJ (B10.BR) mice, 5–8 weeks old, were used for each isolation. Under nembutal anesthesia, the mice were opened by a midline incision. The bile duct was clamped near the duodenum and the pancreas distended by intraductal injection (30-gauge needle) in the proximal common bile duct of 2 ml cold (4°C) Hanks' balanced salt solution containing 1 mg/ml collagenase (Sigma, Type XI). Six pancreases were then

¹ This work was supported by NIH Grant DK-01226-31 and by NIH Training Program Grant 5T32A107163.